ICON CLINICAL RESEARCH GMBH

Their core work

ICON Clinical Research GmbH is the German arm of ICON plc, one of the world's largest Contract Research Organizations (CROs). They run clinical trials on behalf of sponsors — handling protocol design, patient recruitment, regulatory submissions, site monitoring, data management, and safety reporting. In H2020 they appear consistently as a third party to consortium partners, providing the operational machinery that turns a research hypothesis into a regulator-grade clinical study. Their value is execution: they are the team that actually runs the Phase II and Phase III trials embedded in EU health projects.

What they specialise in

How they've shifted over time

In the earlier engagement (MIROCALS, starting 2015) the work centred on neurodegenerative disease and small-molecule immunomodulation — a Phase II proof-of-mechanism study in ALS. From 2017 onwards the portfolio shifted decisively toward advanced therapy medicinal products (ATMPs), specifically placenta-derived cell therapies in PACE and HIPGEN. The trajectory also moved from Phase II toward Phase III, suggesting accumulating experience managing larger, more regulated pivotal studies.

They are moving up the clinical ladder — from Phase II mechanism studies into Phase III pivotal trials of cell-based therapies, positioning them well for future ATMP and regenerative medicine consortia.

How they like to work

ICON never coordinates or takes a direct beneficiary slot in these projects — they enter as a third party, meaning a consortium member subcontracts trial operations to them. They worked with 32 distinct partners across 13 countries in just three projects, typical of a CRO that plugs into whichever academic or industrial sponsor needs pan-European trial execution. Working with them means buying clinical trial delivery capacity, not a research collaborator with an independent scientific agenda.

Connected to 32 consortium partners across 13 European countries via three multicentre trials, reflecting a classic pan-European CRO footprint rather than a geographically concentrated network.

What sets them apart

Unlike academic clinical units or hospital-based trial centres, ICON is a commercial CRO with global regulatory, data management, and pharmacovigilance infrastructure behind its German office. Their distinctive edge in H2020 is the ability to run Phase III-grade trials of advanced therapies (PLX-PAD cell therapy) and rare-disease immunotherapies (IL-2 in ALS) to sponsor standards. A consortium should partner with them when the scientific question is settled and the bottleneck is turning it into an auditable, regulator-ready clinical study.

Highlights from their portfolio

• HIPGEN
  Phase III pivotal trial of placenta-derived cell therapy for hip fracture recovery — the most advanced clinical stage in their H2020 portfolio.
• MIROCALS
  Rare-disease immunotherapy trial combining proof-of-mechanism design with a Phase II efficacy readout in ALS, a notoriously difficult indication.
• PACE
  Multicenter Phase IIb study of HLA-unmatched allogeneic cell therapy, involving logistically complex cross-border manufacturing and delivery.